65,437 trials
Schizophrenia
Primary: Change in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period. — -25.7; -23.6; -28.7; -16.0 Units on a…
Oral Bacteria
Primary: Antimicrobial Species in Plaque(Actinomyces) — 0.023; 0.3881; 0.0538 log CFU (Colony forming units) — p=0.05
Carcinoma, Non-Small-Cell Lung
Primary: 6-month Progression-free Survival — 30.7; 26.4 Percentage of Patients
Liver Transplant
Primary: Percentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation. — 33.3; 32.9…
Asthma
Primary: Early Phase Allergic Response After Treatment With Study Drug in Active and Placebo Patients — 9.3; 5.6; 23.1; 11.8 Percentage of EAR
Coronary Disease
Primary: Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time — 13; 16; 32; 27 participants…
Leukemia · Myelodysplastic Syndromes
Primary: Number of Patients Experiencing Regimen-related Toxicity Events in Study Population — 2; 5 participants
Thromboembolism
Primary: Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE — 30; 27; 34; 32 Participants — p=<0.0001
Smallpox
Primary: The Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine — 77; 112; 76; 91 PRNT50 Titers
Thrombosis, Venous
Primary: Number of Participants With the Indicated Types of Haemorrhages During Hospitalization or Follow-up for Major Orthopaedic Surgery of Lower Limbs (MOSLL) — 7; 10; 0; 3…
Muckle Wells Syndrome
Primary: Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part) — 0; 81.3 percent of participants
Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
Primary: Mean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 6 in Group B — 47.6; 48.1; 55.7; 57.1 Number of Letters
Skin Flora Contamination
Primary: Change in Number of Unique Bacterial Isolates From Pre-skin Preparation to Post-CABG - Sternal Site — -1.34; -1.31 isolates — p=0.655
Smallpox
Primary: Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine — 2; 4; 3; 4 Participants
Atrial Fibrillation
Primary: Number of Participants With Fatal or Life-threatening Major Bleeding Events — 0; 0; 0; 0 Participants